Well, they have three approved oncology drugs and the potential inherent in just rolling out Kyrpolis to foreign markets, for example, is enormous. Remember that CELG essentially addresses the same Multiple Myeloma market and look at their history. Nexavar has potential in thyroid and other cancers beyond its present application in kidney cancer. They have a promising drug which would address auto-immune diseases, ONX914. This would include arthritis, lupus, asthma, etc. You and I will probably be dead before they exhaust the possibilities.